CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement
Rhea-AI Summary
CollPlant (Nasdaq: CLGN) received a Nasdaq notice on March 23, 2026, for failing to meet the $1.00 minimum bid under Nasdaq Listing Rule 5550(a)(2). The company has a 180-calendar day cure period until September 21, 2026 to regain compliance by achieving a $1.00 closing bid for 10 consecutive business days.
The company may seek a second 180-day period if it meets market value and other initial listing standards and notifies Nasdaq of intent to cure, potentially via a reverse share split. Ordinary shares remain listed and tradable.
Positive
- Granted a 180-calendar day compliance period through Sept 21, 2026
- Ordinary shares will remain listed and continue trading on Nasdaq
- Clear remedial path: regain $1.00 closing bid for 10 consecutive business days
Negative
- Closing bid below $1.00 for 30 consecutive business days as of March 23, 2026
- Risk of delisting if compliance not regained within allotted period(s)
- Potential need for a reverse share split to cure bid-price deficiency
Key Figures
Market Reality Check
Peers on Argus
While CLGN was down 1.3%, several biotech peers also declined sharply (e.g., CASI -38.97%, DYAI -11.34%, LSB -20.62%). However, scanner data shows no coordinated sector momentum, suggesting this Nasdaq notice is primarily stock-specific.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 18 | Corporate website update | Positive | +1.7% | Redesigned corporate website to centralize information and highlight rhCollagen pipeline. |
| Mar 11 | Earnings date announcement | Neutral | -1.6% | Set disclosure date for full-year 2025 financial results and related materials. |
| Feb 26 | Patent allowance Korea | Positive | -3.9% | Korean patent allowance for photocurable dermal filler extending protection to 2039. |
| Feb 23 | BioFlex product launch | Positive | -3.2% | Launch of BioFlex ready-to-print rhCollagen kit for DLP 3D bioprinting applications. |
| Feb 17 | Aesthetic market strategy | Positive | -11.9% | Positioning photocurable rhCollagen filler for GLP-1-linked facial volume loss market. |
Recent operational and strategic announcements have often been followed by negative price reactions, with 3 of the last 5 news items seeing declines despite generally constructive updates.
Over the past months, CollPlant reported several business developments, including a Korean patent allowance for its photocurable dermal filler, the launch of the BioFlex 3D bioprinting kit, and targeting a new aesthetic market linked to GLP-1 weight-loss treatments. It also refreshed its corporate website on March 18, 2026 and set a date for full-year 2025 results. Despite largely positive operational news, share reactions were frequently negative, framing today’s Nasdaq minimum bid price notification against a backdrop of sustained price weakness.
Market Pulse Summary
This announcement outlines that CollPlant’s shares remained below the Nasdaq $1.00 minimum bid price for 30 consecutive business days and that the company received a formal deficiency notice. It has 180 calendar days, until September 21, 2026, to regain compliance, potentially followed by another 180-day period. Investors may watch management’s stated review of options, including a possible reverse share split, and monitor progress toward maintaining Nasdaq Capital Market listing standards.
Key Terms
minimum bid price requirement regulatory
nasdaq capital market regulatory
deficiency notification regulatory
AI-generated analysis. Not financial advice.
REHOVOT,
Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180-calendar day compliance period, or until September 21, 2026, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Ordinary Shares must meet or exceed
If the Company is not in compliance by September 21, 2026, the Company may be afforded a second 180-calendar day compliance period. To qualify for this additional time, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse share split, if necessary. If the Company does not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company's Ordinary Shares will be subject to delisting.
The Company intends to monitor the closing bid price of its Ordinary Shares between now and September 21, 2026, and intends to consider available options to cure the deficiency and regain compliance with the minimum bid price requirement within the compliance period. The Company's Ordinary Shares will continue to be listed and trade on the Nasdaq Capital Market during this period, and are unaffected by the receipt of the written notice from Nasdaq.
This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.
About CollPlant
CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine.
In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market. For more information about CollPlant, visit http://www.collplant.com.
Forward-Looking Statements
This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives, plans and strategies, including statements regarding the Company's ability to regain compliance with Nasdaq's minimum bid price requirement, the timing and potential effectiveness of any actions the Company may undertake to cure such deficiency, including the implementation of a reverse share split, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's ability to regain compliance with the Nasdaq minimum bid price requirement, the Company's history of significant losses, its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the Company's expectations regarding the costs and timing of commencing and/or concluding pre-clinical and clinical trials with respect to breast implants, tissues and organs which are based on its rhCollagen based BioInk and other products for medical aesthetics; the Company's or it strategic partners' ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based bioink and medical aesthetics products or product candidates including, but not limited to acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products, in 3D bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations, including its partnership with AbbVie and its ability to continue to receive milestone and royalties payments under the AbbVie agreement; the Company's reliance on third parties to conduct some or all aspects of its product development and manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates, including, with respect to the ongoing war in
Contacts:
Eran Rotem
Deputy CEO & CFO
Tel: + 972-73-2325600
Email: Eran@CollPlant.com
Logo - https://mma.prnewswire.com/media/2217353/CollPlant_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/collplant-biotechnologies-receives-nasdaq-notification-regarding-minimum-bid-requirement-302723716.html
SOURCE CollPlant
FAQ
What did CollPlant (CLGN) announce about the Nasdaq minimum bid requirement on March 24, 2026?
How long does CollPlant (CLGN) have to regain compliance with Nasdaq's $1.00 rule?
What happens if CollPlant (CLGN) does not meet Nasdaq's minimum bid requirement by September 21, 2026?
Will CollPlant (CLGN) shares be delisted immediately after the Nasdaq notice?
Could CollPlant (CLGN) use a reverse share split to regain Nasdaq compliance?
